The platform, which provides analysis and data of each patient, has served more than one million users.
Glooko was born in 2011 in California, at the hands of its three founders Yogen Dalal, Alndeep Madra and Chamath Palihapitiya, each of them impacted individually by diabetes disease.The platform has announced the recent closure of a series C series investment valued at $ 35 million, led by Georgian Partners and other investors mostly related to the world of health.
In addition to the previous investment rounds, the platform has a total sum of 71 million dollars, which as they have declared in the official statement, will be destined to expand its commercialization and marketing and development equipment.They also plan to internationalize their product to France, the United Kingdom, Germany, and jump to the Asian continent and the Middle East.
“With this capital, we will accelerate our investment in medical solutions, which aimsHealth so that they can support patients in the periods between visits to the clinic, ”said the CEO of Glooko, Rick Altinger, for Techcrunch.
an app to give greater control to the patient and reduce the cost of urgent visits and hospitalizations
Glooko integrates a very useful series of data so that the diabetic patient can control their disease outside the health center.Specifically, it offers blood glucose levels, diet and exercise guidelines, biometric, insulin dose monitoring and medication information.
The application, available for mobiles and tablets, is compatible with about thirty glucose measurement devices that the patient can acquire.In addition, users can add personal information such as meals or exercise they do and share all this content with the medical team that is treating you.
The ultimate goal of the initiative is to reduce emergency visits to health centers and hospitalization costs that involve a bad monitoring of pharmaceutical treatments.On the other hand, Glooko is continuously closing agreements and collaborations with companies in the health sector, such as suppliers or other startups such as FIT4D, which provide a ‘coaching’ for diabetic patients.
The importance of rigorous control
According to the World Health Organization (WHO), diabetes cases have increased from 108 million in 1980 to 422 million in 2014, and 50% are expected to increase in the next 20 years.Those affected by the disease suffer a high risk of blindness, renal failure, myocardial infarction, stroke and amputation of the lower limbs, being also diabetes the direct cause of death of 1.5 million people in 2012.
Platforms such as Glooko seek to facilitate the rigorous but necessary control that patients should carry after being diagnosed with diabetes;A control that includes the maintenance of normal glucose levels in the blood through the daily injections of insulin or insulin pumps - which release the substance through an attached device.
The monitoring of medical visits and contact with health professionals is also an essential factor to avoid any complication of the disease, something that several startups in the world of medicine are looking to improve with platforms and applications that connect the patient with theHealth centers
